Y-mAbs Therapeutics Stock Soars 20% on Earnings Growth Expectations

On March 24, 2025, Y-mAbs Therapeutics' stock price surged 20% in pre-market trading, indicating a significant bullish sentiment among investors.

Y-mAbs Therapeutics is expected to see earnings growth in the coming year, with projections moving from a loss of $0.65 per share to a loss of $0.59 per share. This improvement in earnings, though still in the red, suggests that the company is making progress towards profitability.

Analysts have been adjusting their expectations for Y-mAbs Therapeutics. HC Wainwright has lowered its expectations for the company, which could be a reflection of recent market conditions or internal company developments. However, it is important to note that analyst ratings are just one factor to consider when evaluating a stock's potential.